Literature DB >> 12692930

Intrapleural administration of a large amount of diluted fibrin glue for intractable pneumothorax. A clinical study based on 57 cases: including 2 unsuccessful cases.

Takahiro Kinoshita1, Shinichiro Miyoshi, Takaomi Suzuma, Teruhisa Sakurai, Katsumi Enomoto, Tatsuya Yoshimasu, Shinzi Maebeya, Masanobu Juri, Yoshitaka Okamura.   

Abstract

OBJECTIVE: Pleurodesis using chemical agents has been applied to high-risk patients with pneumothorax. This treatment, however, is sometimes unsuccessful in patients with intractable pneumothorax. We have developed intrapleural administration of diluted fibrin glue as an effective treatment for such patients.
METHODS: Fibrin glue was diluted 4-fold with saline and/or contrast media. Pleurodesis with a large amount of the diluted fibrin glue was performed in 55 high risk patients (57 cases, bil.2 patients) with intractable pneumothorax.
RESULTS: The air leaks were stopped by administration of the glue in all except 2 patients. During the follow-up period, a recurrence rate of 10.5% was observed. These recurrent pneumothoraces were successfully treated using the same procedure with no further recurrence. Pyrexia (12.3%) and chest discomfort (8.8%) were observed as side effects, and there was no occurrence of severe chest pain or thoracic empyema.
CONCLUSIONS: These results suggested that intrapleural administration of a large amount of diluted fibrin glue was an effective treatment for intractable pneumothoraces in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692930     DOI: 10.1007/BF02719165

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  28 in total

1.  The influence of fibrin stabilizing factor on the growth of fibroblasts in vitro and wound healing.

Authors:  E BECK; F DUCKERT; M ERNST
Journal:  Thromb Diath Haemorrh       Date:  1961-12-15

2.  Complicated pneumothorax: short- and long-term results of endoscopic fibrin pleurodesis.

Authors:  H Hauck; P G Bull; N Pridun
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

3.  Chemical pleurodesis with doxycycline 1 g.

Authors:  J D Herrington; M L Gora-Harper; R K Salley
Journal:  Pharmacotherapy       Date:  1996 Mar-Apr       Impact factor: 4.705

4.  Respiratory failure due to insufflated talc.

Authors:  J R Campos; E C Werebe; F S Vargas; F B Jatene; R W Light
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

5.  The effectiveness of fibrin glue sealant for reducing experimental pulmonary ari leak.

Authors:  P M McCarthy; V F Trastek; D G Bell; G R Buttermann; J M Piehler; W S Payne; L H Weiland; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1988-02       Impact factor: 4.330

6.  Autologous blood for pleurodesis in recurrent and chronic spontaneous pneumothorax.

Authors:  C L Robinson
Journal:  Can J Surg       Date:  1987-11       Impact factor: 2.089

7.  Pneumothorax. Results of thoracoscopy and pleurodesis with talc poudrage and thoracotomy.

Authors:  J A van de Brekel; V A Duurkens; R G Vanderschueren
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

8.  A comparison of rotation and nonrotation in tetracycline pleurodesis.

Authors:  S R Dryzer; M L Allen; C Strange; S A Sahn
Journal:  Chest       Date:  1993-12       Impact factor: 9.410

9.  Clinical experience with fibrin glue in cardiac surgery.

Authors:  G Köveker; E R de Vivie; K D Hellberg
Journal:  Thorac Cardiovasc Surg       Date:  1981-10       Impact factor: 1.827

10.  Temporal evolution of pleural fibrosis induced by intrapleural minocycline injection.

Authors:  C S Sassoon; R W Light; F S Vargas; S E Gruer; N S Wang
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

View more
  1 in total

Review 1.  Effectiveness of chemical pleurodesis in spontaneous pneumothorax recurrence prevention: a systematic review.

Authors:  R J Hallifax; A Yousuf; H E Jones; J P Corcoran; I Psallidas; N M Rahman
Journal:  Thorax       Date:  2016-11-01       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.